Cover Image

Targeting inflammation in non-small cell lung cancer through drug repurposing

Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in te...

Full description

Saved in:
Bibliographic Details
Main Authors: Rajasegaran, Thiviyadarshini, How, Chee Wun, Saud, Anoosha, Ali, Azhar, Lim, Jonathan Chee Woei
Format: Article
Published: Multidisciplinary Digital Publishing Institute 2023
Online Access:http://psasir.upm.edu.my/id/eprint/109107/
https://www.mdpi.com/1424-8247/16/3/451
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.upm.eprints.109107
record_format eprints
spelling my.upm.eprints.1091072024-08-28T04:22:50Z http://psasir.upm.edu.my/id/eprint/109107/ Targeting inflammation in non-small cell lung cancer through drug repurposing Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives. Multidisciplinary Digital Publishing Institute 2023-03-16 Article PeerReviewed Rajasegaran, Thiviyadarshini and How, Chee Wun and Saud, Anoosha and Ali, Azhar and Lim, Jonathan Chee Woei (2023) Targeting inflammation in non-small cell lung cancer through drug repurposing. Pharmaceuticals, 16 (3). art. no. 451. pp. 1-30. ISSN 1424-8247 https://www.mdpi.com/1424-8247/16/3/451 10.3390/ph16030451
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
description Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives.
format Article
author Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
spellingShingle Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
Targeting inflammation in non-small cell lung cancer through drug repurposing
author_facet Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
author_sort Rajasegaran, Thiviyadarshini
title Targeting inflammation in non-small cell lung cancer through drug repurposing
title_short Targeting inflammation in non-small cell lung cancer through drug repurposing
title_full Targeting inflammation in non-small cell lung cancer through drug repurposing
title_fullStr Targeting inflammation in non-small cell lung cancer through drug repurposing
title_full_unstemmed Targeting inflammation in non-small cell lung cancer through drug repurposing
title_sort targeting inflammation in non-small cell lung cancer through drug repurposing
publisher Multidisciplinary Digital Publishing Institute
publishDate 2023
url http://psasir.upm.edu.my/id/eprint/109107/
https://www.mdpi.com/1424-8247/16/3/451
_version_ 1809142967204577280
score 13.211869

Similar Items